Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.
The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.
The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback